Entities / Company
Elanco.
American healthcare company
- Reports this week
- 1
- Active events
- 1
- Connections
- 82
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
Elanco is utilizing a manufacturing site in Doniphan County, Kansas, and the expansion is expected to benefit the local county economy.Some support1 report
-
Elanco, a company based in Indianapolis, filed required documents with the SEC on August 19, 2026.Some support1 report
-
Elanco filed required insider trading disclosures with the relevant authorities on August 18, 2026.Some support1 report
-
Elanco reported market share gains driven by its successful innovation portfolio within the animal health industry.Some support3 reports
-
CEO Jeffrey N. Simmons purchased Elanco shares, and Norges Bank acquired a new stake in the company, disclosed via SEC filing.Some support1 report
Gone quiet
No new reports in 90+ days-
FDA approved combination clearances for Elanco's Experior use on June 27, 2025.Some support2 reports
-
Elanco Ventures established a CVC platform in Indianapolis to invest in animal health, leveraging the One Health Innovation District.Some support2 reports
-
Elanco leverages proximity of partnerships in Indianapolis.Some support2 reports
-
Microsoft, Elanco, Monster Beverage, and Jazz Pharmaceuticals were cited in thematic investing as examples of diverse winners in the pharmaceuticals segment.Some support2 reports
-
Elanco was originally a division of Eli Lilly, and Jeff Simmons currently serves as the President and CEO of Elanco.Some support9 reports
-
Trump pledged to unleash American oil and gas production, involving Elanco.Some support1 report
-
Bank of America probed Elanco regarding its innovation revenue guidance on June 30, 2025.Speculative1 report
-
Global license agreement accelerates commercialization of NUZ-001 for neurodegenerative diseases.Speculative1 report
-
Elanco developed a vaccine for canine influenza protection and received approval from the USDA for market release.Speculative2 reports
-
Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.Some support1 report
-
Elanco and U.S. Physical Therapy were classified as stocks in the Medical Healthcare sector as of July 24, 2025.Some support1 report
-
Elanco secures various market approvals for its product Zenrelia, including availability in the US, EU, Brazil, Canada, and Japan.Some support1 report
-
Wall Street analysts predicted specific quarterly earnings and revenue metrics for Elanco.Some support1 report
-
Elanco's stock performance was compared to the broader market index on August 7, 2025.Some support1 report
-
Accelerated customer purchases in China benefited sales for a company, while Quattro saw increased sell-through in the U.S., coinciding with a comment from William Blair on Elanco's earnings.Some support1 report
-
Elanco attended a conference hosted by Morgan Stanley on August 26, 2025.Some support2 reports
-
Elanco and Splenda announced support for the Nutrition Secure Indianapolis program, marking a specific corporate action in the city.Some support1 report
-
Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Elanco this week
News at the entities that move Elanco most-
SEC StructuralHoward sold shares of Yum China stock, while the company filed disclosures with the SEC and saw a new investment.Moves Elanco
-
Eli Lilly and Company StructuralMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves Elanco
-
FDA StructuralFDA conducted a nationwide product recall involving toothpaste flavored with strawberry and watermelon, featuring Barbie characters.Moves Elanco
-
Goldman Sachs TransactionalGoldman Sachs and Google announced a partnership to provide AI training and tools.Moves Elanco
-
Purdue University OperationalArrive AI, led by Dan O'Toole, is testing its technology at Purdue University.Moves Elanco
-
Lancaster County Shared contextLocal officials and postal workers in Dauphin and Lancaster counties are involved in administrative and ballot issues.Moves Elanco
Connections
The 21 strongest of 82, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Eli Lilly and Company Structural
Elanco was historically a division and subsidiary of Eli Lilly and Company.
-
Jeffrey N. Simmons Structural
Jeffrey N. Simmons serves as the CEO of Elanco.
-
Jeff Simmons Structural
Jeff Simmons holds the executive leadership role of CEO and President at Elanco.
-
SEC Structural
Elanco is subject to mandatory disclosure and regulatory oversight by the SEC.
-
Zoetis Operational
Elanco and Zoetis are direct competitors operating in the animal health and veterinary dermatology markets.
-
FDA Structural
The FDA provides necessary regulatory clearances and oversight for Elanco's products and market operations.
-
Todd Young Operational
Todd Young served as an advisor and CFO for Elanco, managing cost control.
-
Jazz Pharmaceuticals Operational
The two companies actively compete and operate within the specialized pharmaceutical market segment.
Show all 21 connections
-
Kelso Transactional
Elanco sponsors the Kelso Ram Sales event.
-
Norges Bank Transactional
Norges Bank acquired a new stake in Elanco.
-
Indiana Mentioned together
The relationship is based on the shared context that Indiana possesses expertise in human, animal, and plant health.
-
Lancaster County Shared context
The relationship is defined by a shared local context through involvement in the Library Board of Trustees in Lancaster County.
-
Monster Beverage Mentioned together
The entities are co-mentioned in articles grouping them thematically as diverse growth stocks and winners.
-
Doniphan County Shared context
Elanco's expansion provides economic benefits to Doniphan County.
-
Indianapolis Shared context
Elanco is based in Indianapolis and actively participates in local innovation and health programs.
-
Kansas Shared context
Elanco utilizes a manufacturing site located within the state of Kansas.
-
Buy Shared context
Elanco conducts business operations within the location of Buy, as required for insider trading disclosures.
-
Purdue University Operational
Both Purdue University and Elanco anchor the One Health Research Institute.
-
Texas Shared context
Elanco operates within the agricultural context of Texas, where livestock health issues occur.
-
Goldman Sachs Transactional
Goldman Sachs initiated a buy recommendation/investment on Elanco.
-
Centers for Disease Control Mentioned together
The provided evidence does not describe any relationship or coupling between the Centers for Disease Control and Elanco.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
4 events- Elanco is utilizing a manufacturing site in Doniphan County, Kansas, and the expansion is expected to benefit the local county economy.
- Elanco, a company based in Indianapolis, filed required documents with the SEC on August 19, 2026.
- Elanco filed required insider trading disclosures with the relevant authorities on August 18, 2026.
- Elanco reported market share gains driven by its successful innovation portfolio within the animal health industry.
July 2026
1 eventShow 1 earlier month
June 2026
18 events- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- Elanco Ventures established a CVC platform in Indianapolis to invest in animal health, leveraging the One Health Innovation District.
- Elanco leverages proximity of partnerships in Indianapolis.
- Microsoft, Elanco, Monster Beverage, and Jazz Pharmaceuticals were cited in thematic investing as examples of diverse winners in the pharmaceuticals segment.
- Elanco was originally a division of Eli Lilly, and Jeff Simmons currently serves as the President and CEO of Elanco.
- Trump pledged to unleash American oil and gas production, involving Elanco.
- Bank of America probed Elanco regarding its innovation revenue guidance on June 30, 2025.
- Global license agreement accelerates commercialization of NUZ-001 for neurodegenerative diseases.
- Elanco developed a vaccine for canine influenza protection and received approval from the USDA for market release.
- Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.
- Elanco and U.S. Physical Therapy were classified as stocks in the Medical Healthcare sector as of July 24, 2025.
- Elanco secures various market approvals for its product Zenrelia, including availability in the US, EU, Brazil, Canada, and Japan.
- Wall Street analysts predicted specific quarterly earnings and revenue metrics for Elanco.
- Elanco's stock performance was compared to the broader market index on August 7, 2025.
- Accelerated customer purchases in China benefited sales for a company, while Quattro saw increased sell-through in the U.S., coinciding with a comment from William Blair on Elanco's earnings.
- Elanco attended a conference hosted by Morgan Stanley on August 26, 2025.
- Elanco and Splenda announced support for the Nutrition Secure Indianapolis program, marking a specific corporate action in the city.
- Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.